The Australian Innovation Challenge has recognised the revolutionary Nanopatch technology with top honours at an award ceremony held last week, winning the manufacturing and high-tech design category.

 

The invention of Nanopatch a needle-free vaccination to replace needles and syringes, is being commercialised by Vaxxas Pty Ltd, a company established with funding from the IIF. Leading the venture capital investment in Vaxxas is IIF manager OneVentures.

 

Vaxxas will stage clinical trials within the next three years. Nanopatch™, created by researchers at the University of Queensland.

 

“Nanopatch™ will use less vaccine than a syringe, prevent needle-stick injuries and eliminate the need for vaccines to be refrigerated. Its greatest impact will be in countries where deaths from preventable infectious diseases are far too high,” Innovation Minister Senator Kim Carr said.

 

“This is cutting-edge research and innovation and is exactly why the IIF was created – IIF helps our great researchers and early-stage companies to commercialise such important products. Nanopatch™ is a perfect example of the power of Australian innovation.”

 

More information on the challenge can be found here